Bromide

Bromide

SCHEMBL286655

CC(C)CCC[P+](c1ccccc1)(c1ccccc1)c1ccccc1.[Br-]

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.58
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
TSHR P16473 1/20 0.45
CYP2C19 P33261 1/20 0.45
CHRNA7 P36544 9/20 0.41
TRAP1 Q12931 2/20 0.41
MEN1 O00255 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28039442 0.96 HIF1A (0.58) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2410568 0.94 HIF1A (0.56) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL10842501 0.92 HIF1A (0.50) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL10375203 0.92 HIF1A (0.54) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2449969 0.89 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL164818 0.86 HIF1A (0.71) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL11440559 0.84 HIF1A (0.56) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Hydrochloric Acid SCHEMBL7970758 0.84 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL2446042 0.84 HIF1A (0.74) HIF1AALDH1A1CYP1A2CYP2D6TSHR
Bromide SCHEMBL11753850 0.83 HIF1A (0.54) HIF1AALDH1A1CYP1A2CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464048-B2 5-oxo-ETE receptor antagonist compounds FLORIDA INSTITUTE OF TECHNOLOGY (US) 2016-10-11 US disclosed
EP-2495242-B1 NOVEL VASCULAR LEAK INHIBITOR UNIV YONSEI IACF (KR) 2016-05-04 EP disclosed
CN-102656153-B Novel vascular leak inhibitor UNIV YONSEI IACF (KR) 2015-02-18 CN disclosed
US-8889840-B2 Vascular leakage inhibitor INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2014-11-18 US disclosed
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-10-30 US disclosed
EP-2427430-B1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS UNIV MCGILL (CA) 2014-09-10 EP disclosed
US-8809382-B2 5-oxo-ETE receptor antagonist compounds THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) 2014-08-19 US disclosed
US-20120245110-A1 VASCULAR LEAKAGE INHIBITOR CURACLE CO., LTD. (KR) 2012-09-27 US disclosed
EP-2495242-A2 NOVEL VASCULAR LEAK INHIBITOR Industry-Academic Cooperation Foundation, Yonsei University (KR) 2012-09-05 EP disclosed
CN-102656153-A Novel vascular leak inhibitor HANDOK PHARMACEUTICALS CO LTD 2012-09-05 CN disclosed
US-5214129-A Amidation of a protected amino acid by an di-O-protected dihydroxy-containing amine and coupling with a carboxylic acid; deprotecting; renin inhibitors; hypotensive agents ABBOTT LABORATORIES (US) 1993-05-25 US disclosed
US-5091575-A Renin inhibitor ABBOTT LABORATORIES (US) 1992-02-25 US disclosed
US-5032577-A Hypotensive ABBOTT LABORATORIES (US) 1991-07-16 US disclosed
EP-0295294-A4 PEPTIDYLAMINODIOLS. ABBOTT LAB (US) 1990-04-10 EP disclosed
US-4880892-A PHOSPHONIUM OR PHOSPHORANE CATALYST, PROTECTIVE COATINGS CIBA-GEIGY CORPORATION (US) 1989-11-14 US disclosed
US-4845079-A HYPOTENSIVE, RENIN INHIBITION ABBOTT LABORATORIES 1989-07-04 US disclosed
EP-0295294-A1 PEPTIDYLAMINODIOLS ABBOTT LABORATORIES (US) 1988-12-21 EP disclosed
WO-1988005050-A1 PEPTIDYLAMINODIOLS ABBOTT LABORATORIES (US) 1988-07-14 WO disclosed
EP-0229667-A2 Peptidylaminodiols ABBOTT LABORATORIES (US) 1987-07-22 EP disclosed
EP-0189203-A2 Peptidylaminodiols ABBOTT LABORATORIES (US) 1986-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323535-A1 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS OXER1, PTGIR, EDNRA HIF1A 867/4885ALDH1A1 1506/4885CYP1A2 517/4885
US-20120245110-A1 VASCULAR LEAKAGE INHIBITOR LIPG, VCAM1, ARHGDIB HIF1A 2987/4885ALDH1A1 4675/4885CYP1A2 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.